These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 29386072)
1. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. Lai J; Xu P; Jiang X; Zhou S; Liu A BMC Cancer; 2017 Jul; 17(1):507. PubMed ID: 28754096 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas. Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443 [TBL] [Abstract][Full Text] [Related]
4. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646 [TBL] [Abstract][Full Text] [Related]
5. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. Huang H; Zhu J; Yao M; Kim TM; Yoon DH; Cho SG; Eom HS; Lim ST; Yeh SP; Song Y; Kwong YL; Kim JS; Jin J; Shi Y; Kim H; Qing M; Zhou T; Gao G; Dong Z; Qi M; Kim WS J Hematol Oncol; 2021 Feb; 14(1):25. PubMed ID: 33588922 [TBL] [Abstract][Full Text] [Related]
7. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405 [TBL] [Abstract][Full Text] [Related]
8. Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. Cho J; Kim SJ; Park WY; Kim J; Woo J; Kim G; Yoon SE; Ko YH; Kim WS Mod Pathol; 2020 Apr; 33(4):603-615. PubMed ID: 31653980 [TBL] [Abstract][Full Text] [Related]
9. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Kwong YL; Chan TSY; Tan D; Kim SJ; Poon LM; Mow B; Khong PL; Loong F; Au-Yeung R; Iqbal J; Phipps C; Tse E Blood; 2017 Apr; 129(17):2437-2442. PubMed ID: 28188133 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703 [TBL] [Abstract][Full Text] [Related]
11. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is? Goldstein DA; Bilal U; Prasad V Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268 [No Abstract] [Full Text] [Related]
13. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900 [TBL] [Abstract][Full Text] [Related]
14. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. O'Neil BH; Wallmark JM; Lorente D; Elez E; Raimbourg J; Gomez-Roca C; Ejadi S; Piha-Paul SA; Stein MN; Abdul Razak AR; Dotti K; Santoro A; Cohen RB; Gould M; Saraf S; Stein K; Han SW PLoS One; 2017; 12(12):e0189848. PubMed ID: 29284010 [TBL] [Abstract][Full Text] [Related]
15. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Kim SJ; Lim JQ; Laurensia Y; Cho J; Yoon SE; Lee JY; Ryu KJ; Ko YH; Koh Y; Cho D; Lim ST; Enemark MB; D'Amore F; Bjerre M; Ong CK; Kim WS Blood; 2020 Dec; 136(24):2754-2763. PubMed ID: 32766875 [TBL] [Abstract][Full Text] [Related]
16. Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data. Kranawetter M; Röhrich S; Müllauer L; Obermair H; Reinthaller A; Grimm C; Sturdza A; Köstler WJ; Polterauer S Int J Gynecol Cancer; 2018 Jul; 28(6):1196-1202. PubMed ID: 29787422 [TBL] [Abstract][Full Text] [Related]
17. Updating targets for natural killer/T-cell lymphoma immunotherapy. Xue W; Zhang M Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584 [TBL] [Abstract][Full Text] [Related]
18. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606 [TBL] [Abstract][Full Text] [Related]